Smith Jason Drew, General Counsel of UroGen Pharma Ltd. ($URGN), made five open market sales of company shares in the last year, totaling $320 thousand. His most recent sale occurred on February 3, 2026. These transactions rank 7,412th out of 11,678 insiders by sale value, below the average of $8.6 million across about six sales per insider. He reported no open market purchases.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan. 31, 2026 | UroGen Pharma Ltd. | $URGN | Smith Jason Drew | General Counsel | M | Restricted Stock Units | 3333 | $0.00 | 6,667.0000 | 48,057,386 | 33.33% | 0.01% |
| Jan. 31, 2026 | UroGen Pharma Ltd. | $URGN | Smith Jason Drew | General Counsel | M | Ordinary Shares | 6667 | $0.00 | 49,972.0000 | 48,057,386 | 15.40% | 0.01% |
| Feb. 3, 2026 | UroGen Pharma Ltd. | $URGN | Smith Jason Drew | General Counsel | S | Ordinary Shares | 3217 | $19.69 | 55,588.0000 | 48,057,386 | 5.47% | 0.01% |
| Jan. 31, 2026 | UroGen Pharma Ltd. | $URGN | Smith Jason Drew | General Counsel | M | Restricted Stock Units | 5500 | $0.00 | 5,500.0000 | 48,057,386 | 50.00% | 0.01% |
| Jan. 31, 2026 | UroGen Pharma Ltd. | $URGN | Smith Jason Drew | General Counsel | A | Restricted Stock Units | 32609 | $0.00 | 32,609.0000 | 48,057,386 | 9999.99% | 0.07% |
| Jan. 31, 2026 | UroGen Pharma Ltd. | $URGN | Smith Jason Drew | General Counsel | M | Restricted Stock Units | 6667 | $0.00 | 0.0000 | 48,057,386 | 100.00% | 0.01% |
| Jan. 31, 2026 | UroGen Pharma Ltd. | $URGN | Smith Jason Drew | General Counsel | M | Ordinary Shares | 5500 | $0.00 | 55,472.0000 | 48,057,386 | 11.01% | 0.01% |
| Feb. 3, 2026 | UroGen Pharma Ltd. | $URGN | Smith Jason Drew | General Counsel | S | Ordinary Shares | 2654 | $19.69 | 52,934.0000 | 48,057,386 | 4.77% | 0.01% |
| Jan. 31, 2026 | UroGen Pharma Ltd. | $URGN | Smith Jason Drew | General Counsel | M | Ordinary Shares | 3333 | $0.00 | 58,805.0000 | 48,057,386 | 6.01% | 0.01% |
| Feb. 3, 2026 | UroGen Pharma Ltd. | $URGN | Smith Jason Drew | General Counsel | S | Ordinary Shares | 1608 | $19.69 | 51,326.0000 | 48,057,386 | 3.04% | 0.00% |
| Sept. 8, 2025 | UroGen Pharma Ltd. | $URGN | Smith Jason Drew | General Counsel | S | Ordinary Shares | 1520 | $19.11 | 43,305.0000 | 47,030,820 | 3.39% | 0.00% |
| Sept. 7, 2025 | UroGen Pharma Ltd. | $URGN | Smith Jason Drew | General Counsel | M | Restricted Stock Units | 3333 | $0.00 | 3,334.0000 | 47,030,820 | 49.99% | 0.01% |
| Sept. 7, 2025 | UroGen Pharma Ltd. | $URGN | Smith Jason Drew | General Counsel | M | Ordinary Shares | 3333 | $0.00 | 44,825.0000 | 47,030,820 | 8.03% | 0.01% |
| July 28, 2025 | UroGen Pharma Ltd. | $URGN | Smith Jason Drew | General Counsel | M | Ordinary Shares | 16500 | $0.00 | 49,014.0000 | 47,030,820 | 50.75% | 0.04% |
| July 28, 2025 | UroGen Pharma Ltd. | $URGN | Smith Jason Drew | General Counsel | S | Ordinary Shares | 7522 | $19.14 | 41,492.0000 | 47,030,820 | 15.35% | 0.02% |
| Jan. 31, 2025 | UroGen Pharma Ltd. | $URGN | Smith Jason Drew | General Counsel | M | Restricted Stock Units | 5500 | $0.00 | 11,000.0000 | 47,030,820 | 33.33% | 0.01% |
| Jan. 31, 2025 | UroGen Pharma Ltd. | $URGN | Smith Jason Drew | General Counsel | M | Ordinary Shares | 2500 | $0.00 | 27,726.0000 | 47,030,820 | 9.91% | 0.01% |
| Jan. 31, 2025 | UroGen Pharma Ltd. | $URGN | Smith Jason Drew | General Counsel | S | Ordinary Shares | 1258 | $11.14 | 26,468.0000 | 47,030,820 | 4.54% | 0.00% |
| Jan. 31, 2025 | UroGen Pharma Ltd. | $URGN | Smith Jason Drew | General Counsel | M | Ordinary Shares | 6667 | $0.00 | 33,135.0000 | 47,030,820 | 25.19% | 0.01% |
| Jan. 31, 2025 | UroGen Pharma Ltd. | $URGN | Smith Jason Drew | General Counsel | S | Ordinary Shares | 3354 | $11.14 | 29,781.0000 | 47,030,820 | 10.12% | 0.01% |
| Jan. 31, 2025 | UroGen Pharma Ltd. | $URGN | Smith Jason Drew | General Counsel | M | Ordinary Shares | 5500 | $0.00 | 35,281.0000 | 47,030,820 | 18.47% | 0.01% |
| Jan. 31, 2025 | UroGen Pharma Ltd. | $URGN | Smith Jason Drew | General Counsel | S | Ordinary Shares | 2767 | $11.14 | 32,514.0000 | 47,030,820 | 7.84% | 0.01% |
| Jan. 31, 2025 | UroGen Pharma Ltd. | $URGN | Smith Jason Drew | General Counsel | M | Restricted Stock Units | 2500 | $0.00 | 0.0000 | 47,030,820 | 100.00% | 0.01% |
| Jan. 31, 2025 | UroGen Pharma Ltd. | $URGN | Smith Jason Drew | General Counsel | M | Restricted Stock Units | 6667 | $0.00 | 6,667.0000 | 47,030,820 | 50.00% | 0.01% |
| Jan. 31, 2025 | UroGen Pharma Ltd. | $URGN | Smith Jason Drew | General Counsel | A | Restricted Stock Units | 10000 | $0.00 | 10,000.0000 | 47,030,820 | 9999.99% | 0.02% |
| Sept. 9, 2024 | UroGen Pharma Ltd. | $URGN | Smith Jason Drew | General Counsel | M | Restricted Stock Units | 3333 | $0.00 | 6,667.0000 | 40,501,315 | 33.33% | 0.01% |
| Sept. 9, 2024 | UroGen Pharma Ltd. | $URGN | Smith Jason Drew | General Counsel | S | Ordinary Shares | 1521 | $13.08 | 25,226.0000 | 40,501,315 | 5.69% | 0.00% |
| Sept. 9, 2024 | UroGen Pharma Ltd. | $URGN | Smith Jason Drew | General Counsel | M | Ordinary Shares | 3333 | $0.00 | 26,747.0000 | 40,501,315 | 14.24% | 0.01% |
| Feb. 1, 2024 | UroGen Pharma Ltd. | $URGN | Smith Jason Drew | General Counsel | S | Ordinary Shares | 417 | $15.78 | 18,824.0000 | 36,153,634 | 2.17% | 0.00% |
| Feb. 1, 2024 | UroGen Pharma Ltd. | $URGN | Smith Jason Drew | General Counsel | S | Ordinary Shares | 1248 | $15.78 | 20,076.0000 | 36,153,634 | 5.85% | 0.00% |
| Feb. 1, 2024 | UroGen Pharma Ltd. | $URGN | Smith Jason Drew | General Counsel | S | Ordinary Shares | 3328 | $15.78 | 23,414.0000 | 36,153,634 | 12.44% | 0.01% |
| Jan. 31, 2024 | UroGen Pharma Ltd. | $URGN | Smith Jason Drew | General Counsel | M | Ordinary Shares | 834 | $0.00 | 19,241.0000 | 36,153,634 | 4.53% | 0.00% |
| Jan. 31, 2024 | UroGen Pharma Ltd. | $URGN | Smith Jason Drew | General Counsel | S | Ordinary Shares | 417 | $15.74 | 18,824.0000 | 36,153,634 | 2.17% | 0.00% |
| Jan. 31, 2024 | UroGen Pharma Ltd. | $URGN | Smith Jason Drew | General Counsel | M | Ordinary Shares | 2500 | $0.00 | 21,324.0000 | 36,153,634 | 13.28% | 0.01% |
| Jan. 31, 2024 | UroGen Pharma Ltd. | $URGN | Smith Jason Drew | General Counsel | S | Ordinary Shares | 1248 | $15.74 | 20,076.0000 | 36,153,634 | 5.85% | 0.00% |
| Jan. 31, 2024 | UroGen Pharma Ltd. | $URGN | Smith Jason Drew | General Counsel | M | Ordinary Shares | 6666 | $0.00 | 26,742.0000 | 36,153,634 | 33.20% | 0.02% |
| Jan. 31, 2024 | UroGen Pharma Ltd. | $URGN | Smith Jason Drew | General Counsel | S | Ordinary Shares | 3328 | $15.74 | 23,414.0000 | 36,153,634 | 12.44% | 0.01% |
| Jan. 31, 2024 | UroGen Pharma Ltd. | $URGN | Smith Jason Drew | General Counsel | M | Restricted Stock Units | 834 | $0.00 | 0.0000 | 36,153,634 | 100.00% | 0.00% |
| Jan. 31, 2024 | UroGen Pharma Ltd. | $URGN | Smith Jason Drew | General Counsel | M | Restricted Stock Units | 2500 | $0.00 | 2,500.0000 | 36,153,634 | 50.00% | 0.01% |
| Jan. 31, 2024 | UroGen Pharma Ltd. | $URGN | Smith Jason Drew | General Counsel | M | Restricted Stock Units | 6666 | $0.00 | 13,334.0000 | 36,153,634 | 33.33% | 0.02% |
| Jan. 31, 2024 | UroGen Pharma Ltd. | $URGN | Smith Jason Drew | General Counsel | A | Restricted Stock Units | 16500 | $0.00 | 16,500.0000 | 36,153,634 | 9999.99% | 0.05% |